文献速递痛风与晶体性关节病

痛风达标降尿酸治疗改善健康相关生活质量:一项随机多中心试验的事后分析

Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2025-11-17

该研究为一项为期72周随机试验的事后分析,汇总别嘌醇与非布司他治疗组共878例痛风患者数据;达标降尿酸治疗(ULT)后,健康相关生活质量(HRQoL)总分及躯体功能、活动能力、疼痛领域在24周内显著改善并持续至72周(P<0.001);基线炎症与合并症负担较低者改善更明显。

要点

  • 达标ULT后HRQoL总分及躯体功能、活动能力、疼痛领域在24周内显著改善(P<0.001),并持续至72周。
  • 基线HRQoL较差与较年轻、非白人种族、痛风石(EQ-5D-3L)、较高血尿酸水平及较多合并症相关。
  • 基线C反应蛋白水平较低与合并症评分较低者,72周内HRQoL改善更明显,两个ULT分组间变化相似。

核心结论

  • 痛风达标降尿酸治疗伴随HRQoL改善,24周即可显现并持续至72周。
  • HRQoL获益在躯体功能、活动能力与疼痛领域最突出,在基线炎症与合并症水平较低者中最大。

研究设计与样本

  • 一项为期72周随机多中心试验的事后分析,汇总别嘌醇与非布司他治疗组数据。
  • 共纳入878例参与者,98.9%为男性,平均年龄62.4岁,67.4%自报白人种族。
  • 基线与第24、48、72周施用Veterans RAND-12条目健康调查与EuroQol五维三级量表(EQ-5D-3L)。
  • 采用配对t检验分析随访期间HRQoL变化,多变量线性回归评估基线HRQoL相关因素,广义估计方程识别HRQoL变化决定因素。

主要发现

  • HRQoL总分及躯体功能、活动能力、疼痛领域在72周内显著改善(P<0.001),24周时已见改善。
  • 基线HRQoL较差与较年轻年龄、非白人种族、痛风石(EQ-5D-3L)、较高血尿酸水平及较多合并症相关。
  • 72周ULT期间HRQoL改善相关的基线因素包括较低C反应蛋白水平与较低合并症评分,两个ULT分组间变化相似。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although treat-to-target urate-lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health-related quality of life (HRQoL). We assessed the impact of treat-to-target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL change. METHODS: This was a post hoc analysis of a 72-week randomized trial, pooling data from allopurinol and febuxostat treatment arms. The Veterans RAND-12 Item Health Survey and EuroQol 5-Dimension 3-Level (EQ-5D-3L) were administered at baseline and at 24, 48, and 72 weeks. HRQoL changes over follow-up were examined using paired t-tests. Factors associated with baseline HRQoL were evaluated using multivariable linear regression. General estimating equations were used to identify determinants of HRQoL change over follow-up. RESULTS: Participants (N = 878) in this analysis were 98.9% male, had a mean age of 62.4 years, and 67.4% self-reported White race. HRQoL scores overall, and particularly the domains of physical function, mobility and pain, improved significantly over 72 weeks (P < 0.001) with improvements noted by 24 weeks. Poorer enrollment HRQoL was associated with younger age, non-White race, tophi (for EQ-5D-3L), higher serum urate level, and greater comorbidity. Baseline factors associated with HRQoL improvements over 72 weeks of ULT included lower C-reactive protein level and lower comorbidity scores with similar changes observed by ULT assignment. CONCLUSION: Treat-to-target ULT in gout is accompanied by HRQoL improvements evident by 24 weeks and sustained through 72 weeks. HRQoL gains with treat-to-target ULT are most prominent in the domains of physical function, mobility, and pain and are greatest in those with lower baseline levels of inflammation and comorbidity.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Barry A, England BR, Sayles H, et al. Improvements in Health-Related Quality of Life With Treat-to-Target Urate-Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial. Arthritis Care Res (Hoboken). 2025. PMID: 40771143. doi:10.1002/acr.25618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。